DGX Quest Diagnostics Incorporated Common Stock
$240,56
Fiyat · Ağu 21, 2026
Temel veriler itibarıyla Tem 23, 2026
52 Haftlık Aralık
$171–$246
93% of range
Analist Derecelendirmesi
HOLD
23 analysts
Fiyat Hedefi
$246
+2% upside
P/E (TTM)
27.7
ROE
14.2%
Net Kâr Marjı
9.0%
Quest Diagnostics Incorporated Common Stock Hakkında Wikipedia'dan şirket genel bakışı
Quest Diagnostics Incorporated is an American clinical laboratory. A Fortune 500 company, Quest operates in the United States, Puerto Rico, Mexico, and Brazil. Quest also maintains collaborative agreements with various hospitals and clinics across the globe.
Devamını oku
Quest Diagnostics Incorporated is an American clinical laboratory. A Fortune 500 company, Quest operates in the United States, Puerto Rico, Mexico, and Brazil. Quest also maintains collaborative agreements with various hospitals and clinics across the globe.
As of 2020, the company had approximately 48,000 employees, and it generated more than $7.7 billion in revenue in 2019. The company offers access to diagnostic testing services for cancer, cardiovascular disease, infectious disease, neurological disorders, COVID-19, and employment and court-ordered drug testing.
History
1960–1995
Originally founded as Metropolitan Pathology Laboratory, Inc. in 1967 by Paul A. Brown, MD, the clinical laboratory underwent a variety of name changes. In 1969, the company's name changed to MetPath, Inc. with headquarters in Teaneck, New Jersey. By 1982, MetPath was acquired by what was then known as Corning Glass Works and was subsequently renamed Corning Clinical Laboratories.
1996–2000
On December 31, 1996, Quest Diagnostics became an independent company as a spin-off from Corning. Kenneth W. Freeman was appointed as CEO during this transition. Over the next year, Quest acquired a clinical laboratory division of Branford, Connecticut–based Diagnostic Medical Laboratory, Inc. (DML). Two years later in 1999, Quest added SmithKline Beecham Clinical Laboratories to their subsidiaries; which includes a joint venture ownership with CompuNet Clinical Laboratory. The purchase of SmithKline Beecham also included the lab's medical sample transport airline (ICAO: LBQ, call sign: LABQUEST) originally founded in 1988.
In 1997, Quest and Banner Health formed a joint venture creating the Arizona based Sonora Quest laboratory, a business unit of Laboratory Sciences of Arizona. This entity represents the operations of Quest Diagnostics in the Arizona regional market.
2001–2015
From May 2004 to April 2012, Surya Mohapatra served as the company's President and CEO. In 2007 Quest acquired diagnostic testing equipment company AmeriPath. In response to Mohapatra's resignation after eight years with Quest, former Philips Healthcare CEO Stephen Rusckowski was appointed. Under Rusckowski, Quest Diagnostics teamed up with central New England's largest health care system, UMass Memorial Health Care, to purchase its clinical outreach laboratory.
2016–present
In 2016, Quest collaborated with Safeway to bring testing services to twelve of its stores in California, Maryland, Virginia, Texas and Colorado.
By the end of 2017, Quest, in partnership with Walmart, incorporated laboratory testing in about 15 of their locations in Texas and Florida.
In May 2018, the company announced it will become an in-network laboratory provider to UnitedHealthcare starting in 2019, providing access to 48 million plan members.
In September 2018, Quest moved its headquarters from Madison, where it was located since 2007, to Secaucus, New Jersey.
In November 2018, Quest launched QuestDirect, a consumer-initiated testing service that allows patients to order health and wellness lab testing from home.
In March 2020, the company launched a COVID-19 testing service. As of July 2020, Quest had performed more than 9.2 million COVID-19 molecular tests and 2.8 million serology tests.
In April 2024, Quest has added a new blood screening to their AD-Detect product line. This test will analyze the blood for a specific Alzheimer's protein, pTau-217.
In February 2025, Quest acquired select assets of Fresenius Medical Care's Spectra laboratories. Under a separate agreement, Quest now offers clinical testing and lab services related to dialysis and end-stage kidney disease.
Acquisitions
Partnerships
2005: Forms a strategic alliance with Ciphergen Biosystems to commercialize novel proteomic tests.
Controversies
Quest Diagnostics set a record in April 2009 when it paid $302 million to the government to settle a Medicare fraud case alleging the company sold faulty medical testing kits. It was the largest qui tam (whistleblower) settlement paid by a medical laboratory for manufacturing and distributing a faulty product. In May 2011, Quest paid $241 million to the state of California to settle a False Claims Act case that alleged the company had overcharged Medi-Cal, the state's Medicaid program, and provided illegal kickbacks as incentives for healthcare providers to use Quest labs.
In 2018, Quest Diagnostics was among a number of U.S.–based laboratories linked to inaccuracies of over 200 women's cervical smear tests for CervicalCheck, Ireland's national screening program. Audits of the testing performed by Quest (and another subcontractor, Clinical Pathology Laboratories, Inc. of Austin, Texas) showed a high rate of errors in analysis of samples which led to lawsuits and a government inquiry. Quest and the Irish government continue to settle the resulting lawsuits.
On June 3, 2019, Quest announced that American Medical Collection Agency (AMCA), a billing collections service provider, had informed Quest Diagnostics that an unauthorized user had access to AMCA’s system containing personal information AMCA received from various entities, including from Quest. AMCA provides billing collections services to Optum360, which in turn is a Quest contractor. AMCA later went bankrupt after the breach.
Kaynak: Wikipedia (İngilizce), CC BY-SA 4.0 · Wikipedia'da Görüntüle ↗
DGX Hisse Senedi Özeti Fiyat, piyasa değeri, P/E, EPS, ROE, borç/öz sermaye, 52 haftalık aralık
Fiyat
$240.56
Piyasa Değeri
$26.70B
P/E (TTM)
27.7
EPS (TTM)
$8.75
Gelir (TTM)
$11.04B
Temettü Verimi
1.3%
ROE
14.2%
D/E Borç/Özsermaye
0.8
52 Haftlık Aralık
$171 – $246
DGX Hisse Senedi Fiyat Grafiği Teknik göstergeler ile günlük OHLCV — kaydır, yakınlaştır ve görünümünüzü özelleştirin
Configure
10 Yıllık Performans Gelir, net kar, marjlar ve EPS trendleri
Gelir ve Net Gelir
$11.04B
2016-12-31
→
2025-12-31
Hisse Başına Kâr
$8.75
2016-12-31
→
2025-12-31
Serbest Nakit Akışı
$1.36B
2016-12-31
→
2025-12-31
Marjlar
9.0%
2016-12-31
→
2020-12-31
Değerleme P/E, P/S, P/B, EV/EBITDA oranları — hisse senedi pahalı mı ucuz mu?
Metrik
5 Yıllık trend
DGX
Akran Ortalaması
P/E (TTM)
27.7
26.5
P/S (TTM) (F/S (TTM))
2.4
2.0
P/B (F/D)
3.7
4.9
EV / EBITDA
15.0
—
Price / FCF (Fiyat / Serbest Nakit Akışı)
19.6
—
Kârlılık Brüt, faaliyet ve net kâr marjları; ROE, ROA, ROIC
Metrik
5 Yıllık trend
DGX
Akran Ortalaması
Operating Margin (Faaliyet Kâr Marjı)
14.1%
—
Net Profit Margin (Net Kâr Marjı)
9.0%
4.0%
ROA
6.1%
5.0%
ROE
14.2%
15.2%
ROIC
9.2%
—
Finansal Sağlık Borç, likidite, solventlik — bilanço gücü
Metrik
5 Yıllık trend
DGX
Akran Ortalaması
Debt / Equity (Borç / Öz Sermaye)
0.8
—
Current Ratio (Cari Oran)
1.0
1.6
Quick Ratio (Cari Oran)
0.8
—
Büyüme Gelir, EPS ve net gelir büyümesi: YOY, 3 Yıllık CAGR, 5 Yıllık CAGR
Metrik
5 Yıllık trend
DGX
Akran Ortalaması
Revenue YoY (Gelir Yıllık Bazda)
11.8%
—
Revenue CAGR 3Y (Gelir 3 Yıllık Bileşik Büyüme Oranı)
3.7%
—
Revenue CAGR 5Y (Gelir 5 Yıllık Bileşik Büyüme Oranı)
3.2%
—
EPS YoY (EPS YB)
13.8%
—
Net Income YoY (Net Gelir Yıllık Bazda)
13.9%
—
Sermaye Verimliliği Aktif devir hızı, stok devir hızı, alacak devir hızı
Metrik
5 Yıllık trend
DGX
Akran Ortalaması
Payout Ratio (Temettü Ödeme Oranı)
35.6%
—
Temettüler Temettü verimi, ödeme oranı, temettü geçmişi, 5 Yıllık CAGR
Temettü Verimi
1.3%
Temettü Ödeme Oranı
35.6%
5 Yıllık Temettü CAGR
—
| Ex-tarihi | Miktar |
|---|---|
| 08 Temmuz 2026 | $0,8600 |
| 06 Nisan 2026 | $0,8600 |
| 13 Ocak 2026 | $0,8000 |
| 03 Ekim 2025 | $0,8000 |
| 07 Temmuz 2025 | $0,8000 |
| 07 Nisan 2025 | $0,8000 |
| 14 Ocak 2025 | $0,7500 |
| 04 Ekim 2024 | $0,7500 |
| 08 Temmuz 2024 | $0,7500 |
| 05 Nisan 2024 | $0,7500 |
| 16 Ocak 2024 | $0,7100 |
| 05 Ekim 2023 | $0,7100 |
| 10 Temmuz 2023 | $0,7100 |
| 06 Nisan 2023 | $0,7100 |
| 17 Ocak 2023 | $0,6600 |
| 03 Ekim 2022 | $0,6600 |
| 05 Temmuz 2022 | $0,6600 |
| 05 Nisan 2022 | $0,6600 |
| 18 Ocak 2022 | $0,6200 |
| 04 Ekim 2021 | $0,6200 |
DGX Analist Uzlaşması Boğa ve ayı analist görüşleri, 12 aylık fiyat hedefi, yukarı yönlü potansiyel
AL
23 analist
- Güçlü Al 6 26,1%
- Al 7 30,4%
- Tut 10 43,5%
- Sat 0 0,0%
- Güçlü Sat 0 0,0%
12 Aylık Fiyat Hedefi
15 analist · 2026-08-16
Medyan
$250.00
Şimdi
$240.56
Düşük
$204.00
Yüksek
$265.00
Medyan hedef
$250.00
+3,9%
Ortalama hedef
$245.87
+2,2%
Kazanç Geçmişi EPS gerçekleşen vs tahmin, sürpriz %, kazanma oranı, bir sonraki kazanç tarihi
Ort. Sürpriz
0.09%
| Dönem | EPS Gerçek | EPS Tahmin | Sürpriz |
|---|---|---|---|
| 30 Haziran 2026 | $3.12 | $2.85 | 0.27% |
| 31 Mart 2026 | $2.50 | $2.37 | 0.13% |
| 31 Aralık 2025 | $2.42 | $2.38 | 0.04% |
| 30 Eylül 2025 | $2.60 | $2.53 | 0.07% |
| 30 Haziran 2025 | $2.62 | $2.60 | 0.02% |
| 31 Mart 2025 | $2.21 | $2.17 | 0.04% |
Akran karşılaştırması (GICS alt sektörü) Anahtar metrikler sektördeki benzerlerine karşı
| Hisse Sembolü | Piyasa Değeri | P/E | Gelir YoY | Net Kar Marjı | ROE | Brüt Kar Marjı |
|---|---|---|---|---|---|---|
| DGX | $19.09B | 19.8 | 11.8% | 9.0% | 14.2% | — |
| CVS | $100.87B | 57.1 | 7.8% | 0.44% | 2.4% | — |
| CI | $72.51B | 12.4 | 11.2% | 2.2% | 14.4% | — |
| LH | $20.62B | 24.0 | 7.2% | 6.3% | 10.3% | 28.8% |
| GH | $13.34B | -30.8 | 32.9% | -42.4% | 205.7% | — |
| LH | $20.62B | 24.0 | 7.2% | 6.3% | 10.3% | 28.8% |
| BTSG | $7.20B | 43.0 | 28.2% | 1.5% | 10.8% | 11.8% |
| DVA | $7.79B | 11.5 | 6.5% | 5.5% | -281.8% | — |
| HIMS | — | 63.7 | 59.0% | 5.5% | 23.3% | 73.8% |
| HNGE | $0 | -6.0 | 50.6% | -89.9% | -299.8% | 79.7% |
| CHE | — | 23.3 | 4.1% | 10.5% | 24.4% | — |
Tüm Temeller Tüm metrikler yıla göre — gelir tablosu, bilanço, nakit akışı
Gelir Tablosu 17
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $11.04B | $9.87B | $9.25B | $9.88B | $10.79B | $9.44B | $7.73B | $7.53B | $7.40B | $7.21B | $7.49B | $7.43B | |
| Cost of Revenue | $7.37B | $6.63B | $6.20B | $6.45B | $6.58B | $5.80B | $5.04B | $4.93B | $4.72B | $4.62B | $4.66B | $4.64B | |
| Gross Profit | · | · | · | · | · | $3.63B | $2.69B | $2.60B | $2.68B | $2.90B | $2.84B | $2.80B | |
| SG&A Expense | $1.97B | $1.77B | $1.64B | $1.87B | $1.73B | $1.55B | $1.46B | $1.42B | $1.44B | $1.38B | $1.68B | $1.73B | |
| Operating Expenses | $9.48B | $8.53B | $7.99B | $8.46B | $8.41B | $7.47B | $6.50B | $6.43B | $6.24B | $5.94B | $6.09B | $6.45B | |
| Operating Income | $1.56B | $1.35B | $1.26B | $1.43B | $2.38B | $1.97B | $1.23B | $1.10B | $1.17B | $1.28B | $1.40B | $983M | |
| Interest Expense | · | · | $163M | $148M | $152M | $166M | $180M | $169M | $153M | $144M | $154M | $167M | |
| Interest Income | $13M | $25M | $11M | $10M | $1M | $3M | $5M | $2M | $2M | $1M | $1M | $3M | |
| Other Non-op | $26M | $30M | $20M | $-55M | $369M | $76M | $20M | $-8M | $16M | $-48M | $-143M | $4M | |
| Pretax Income | $1.32B | $1.18B | $1.13B | $1.24B | $2.60B | $1.88B | $1.08B | $926M | $1.03B | $1.09B | $1.10B | $823M | |
| Income Tax | $314M | $273M | $248M | $264M | $597M | $460M | $247M | $182M | $241M | $429M | $373M | $262M | |
| Net Income | $992M | $871M | $854M | $946M | $2.00B | $1.43B | $858M | $736M | $772M | $645M | $709M | $556M | |
| EPS (Basic) | $8.87 | $7.78 | $7.59 | $8.10 | $15.85 | $10.62 | $6.36 | $5.39 | $5.63 | $4.58 | $4.92 | $3.83 | |
| EPS (Diluted) | $8.75 | $7.69 | $7.49 | $7.97 | $15.55 | $10.47 | $6.28 | $5.29 | $5.50 | $4.51 | $4.87 | $3.81 | |
| Shares (Basic) | 111,000,000 | 111,000,000 | 112,000,000 | 116,000,000 | 125,000,000 | 134,000,000 | 134,000,000 | 136,000,000 | 137,000,000 | 140,000,000 | 144,000,000 | 145,000,000 | |
| Shares (Diluted) | 113,000,000 | 113,000,000 | 113,000,000 | 118,000,000 | 128,000,000 | 136,000,000 | 136,000,000 | 139,000,000 | 140,000,000 | 142,000,000 | 145,000,000 | 145,000,000 | |
| EBITDA | $2.13B | $1.84B | $1.70B | $1.86B | $2.79B | $2.33B | $1.56B | $1.41B | $1.44B | $1.53B | $1.70B | $1.30B |
Bilanço 27
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $420M | $549M | $686M | $315M | $872M | $1.16B | $1.19B | $135M | $137M | $359M | $133M | $192M | |
| Receivables | $1.41B | $1.30B | $1.21B | $1.20B | $1.44B | $1.52B | $1.06B | $1.01B | $924M | $926M | $901M | $932M | |
| Inventory | $189M | $188M | $190M | $192M | $208M | $223M | $123M | $99M | $95M | $82M | $84M | $110M | |
| Prepaid Expense | $361M | $351M | $286M | $196M | $223M | $157M | $112M | $144M | $150M | $155M | $207M | $186M | |
| Current Assets | $2.38B | $2.39B | $2.37B | $1.90B | $2.74B | $3.06B | $2.49B | $1.39B | $1.31B | $1.53B | $1.50B | $1.60B | |
| PP&E (Net) | $2.20B | $2.11B | $1.82B | $1.77B | $1.71B | $1.63B | $1.45B | $1.29B | $1.15B | $1.03B | $925M | $933M | |
| PP&E (Gross) | $6.18B | $5.77B | $5.23B | $5.10B | $4.79B | $4.62B | $4.23B | $3.97B | $3.67B | $3.43B | $3.23B | $3.13B | |
| Accum. Depreciation | $3.97B | $3.66B | $3.42B | $3.34B | $3.09B | $2.99B | $2.78B | $2.68B | $2.53B | $2.40B | $2.31B | $2.19B | |
| Goodwill | $8.95B | $8.86B | $7.73B | $7.22B | $7.09B | $6.87B | $6.62B | $6.56B | $6.33B | $6.00B | $5.91B | $6.03B | |
| Intangibles | $1.64B | $1.76B | $1.17B | $1.09B | $1.17B | $1.17B | $1.12B | $1.21B | $1.12B | $949M | $984M | $1.07B | |
| Other Non-current Assets | $270M | $255M | $198M | $144M | $163M | $176M | $160M | $119M | $136M | $148M | $174M | $172M | |
| Total Assets | $16.23B | $16.15B | $14.02B | $12.84B | $13.61B | $14.03B | $12.84B | $11.00B | $10.50B | $10.10B | $9.96B | $9.86B | |
| Accounts Payable | $1.60B | $1.39B | $1.36B | $1.40B | $1.60B | $1.63B | $1.04B | $1.02B | $1.02B | $975M | $1.01B | $1.19B | |
| Accrued Liabilities | $338M | $306M | $287M | $392M | $460M | $356M | $223M | $274M | $246M | $254M | $257M | $277M | |
| Current Liabilities | $2.28B | $2.17B | $1.81B | $1.55B | $1.75B | $1.78B | $1.99B | $1.49B | $1.06B | $981M | $1.17B | $1.71B | |
| Capital Leases | $537M | $535M | $503M | $489M | $494M | $499M | $413M | $0 | · | · | · | · | |
| Deferred Tax | · | · | · | · | · | · | $264M | $243M | $170M | $191M | $157M | $204M | |
| Other Non-current Liabilities | $957M | $938M | $876M | $812M | $792M | $847M | $711M | $745M | $663M | $654M | $514M | $594M | |
| Long-term Debt | $5.67B | $6.22B | $4.71B | $3.98B | $4.01B | $4.01B | $4.77B | $3.89B | $3.78B | $3.73B | $3.65B | $3.74B | |
| Total Debt | $5.67B | $6.22B | $4.71B | $3.98B | $4.01B | $4.01B | $4.77B | $3.89B | $3.78B | $3.73B | $3.65B | $3.76B | |
| Common Stock | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | |
| Retained Earnings | $9.99B | $9.36B | $8.82B | $8.29B | $7.65B | $9.30B | $8.17B | $7.60B | $7.14B | $6.61B | $6.20B | $5.72B | |
| Treasury Stock | $5.18B | $4.86B | $4.83B | $4.67B | $3.45B | $5.37B | $5.22B | $5.00B | $4.78B | $4.46B | $3.96B | $3.81B | |
| AOCI | $-27M | $-88M | $-14M | $-21M | $-14M | $-21M | $-39M | $-59M | $-48M | $-72M | $-38M | $-27M | |
| Stockholders' Equity | $7.17B | $6.78B | $6.31B | $5.89B | $6.44B | $6.76B | $5.64B | $5.22B | $4.92B | $4.63B | $4.68B | $4.30B | |
| Liabilities + Equity | $16.23B | $16.15B | $14.02B | $12.84B | $13.61B | $14.03B | $12.84B | $11.00B | $10.50B | $10.10B | $9.96B | $9.86B | |
| Shares Outstanding | 110,000,000 | 111,000,000 | 111,000,000 | 111,000,000 | 119,000,000 | 133,000,000 | 133,000,000 | 135,000,000 | 135,000,000 | 137,000,000 | 143,000,000 | 144,000,000 |
Nakit Akışı 17
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $570M | $493M | $439M | $437M | $408M | $361M | $329M | $309M | $270M | $249M | $304M | $314M | |
| Stock-based Comp | $88M | $88M | $77M | $77M | $79M | $97M | $56M | $61M | $79M | $69M | $52M | $51M | |
| Deferred Tax | $105M | $13M | $-49M | $1M | $-57M | $85M | $15M | $73M | $9M | $37M | $112M | $23M | |
| Amort. of Intangibles | $154M | $127M | $108M | $120M | $103M | $103M | $96M | $90M | $74M | $72M | $81M | $94M | |
| Restructuring | · | · | · | $55M | $13M | $14M | $-3M | $49M | $30M | $11M | $39M | $43M | |
| Other Non-cash | $131M | $-131M | $-49M | $257M | $-192M | $31M | $-15M | $21M | $45M | $69M | $-367M | $-6M | |
| Operating Cash Flow | $1.89B | $1.33B | $1.27B | $1.72B | $2.23B | $2.00B | $1.24B | $1.20B | $1.18B | $1.12B | $821M | $944M | |
| CapEx | $527M | $425M | $408M | $404M | $403M | $418M | $400M | $383M | $252M | $293M | $263M | $308M | |
| Investing Cash Flow | $-631M | $-2.55B | $-1.06B | $-543M | $21M | $-772M | $-411M | $-801M | $-830M | $-127M | $-362M | $-1.02B | |
| Stock Repurchased | $450M | $151M | $275M | $1.41B | $2.20B | $325M | $353M | $322M | $465M | $590M | $224M | $132M | |
| Net Stock Activity | $-450M | $-151M | $-275M | $-1.41B | $-2.20B | $-325M | $-353M | $-322M | $-465M | $-590M | $-224M | $-132M | |
| Dividends Paid | $353M | $331M | $314M | $305M | $309M | $297M | $286M | $266M | $247M | $223M | $212M | $187M | |
| Financing Cash Flow | $-1.39B | $1.08B | $160M | $-1.73B | $-2.54B | $-1.27B | $225M | $-401M | $-592M | $-738M | $-518M | $86M | |
| Net Change in Cash | $-129M | $-137M | $371M | $-557M | $-286M | · | · | · | $-222M | $226M | $-59M | $5M | |
| Taxes Paid | $169M | $256M | $317M | · | · | · | · | · | · | · | · | · | |
| Free Cash Flow | $1.36B | $909M | $864M | $1.31B | $1.83B | $1.59B | $843M | $817M | $923M | $776M | $547M | $630M | |
| Levered FCF | · | · | $737M | $1.20B | $1.71B | $1.46B | $704M | $681M | $806M | $689M | · | · |
Kârlılık 8
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | · | · | · | · | · | 38.5% | 34.8% | 34.6% | 38.8% | 38.6% | 37.9% | 37.6% | |
| Operating Margin | 14.1% | 13.6% | 13.6% | 14.4% | 22.1% | 20.9% | 15.9% | 14.6% | 15.1% | 17.0% | 18.7% | 13.2% | |
| Net Margin | 9.0% | 8.8% | 9.2% | 9.6% | 18.5% | 15.2% | 11.1% | 9.8% | 10.0% | 8.6% | 9.5% | 7.5% | |
| Pretax Margin | 11.9% | 11.9% | 12.2% | 12.5% | 24.1% | 20.0% | 13.9% | 12.3% | 13.4% | 14.4% | 14.7% | · | |
| EBITDA Margin | 19.3% | 18.6% | 18.4% | 18.9% | 25.9% | 24.7% | 20.2% | 18.7% | 18.6% | 20.3% | 22.7% | 17.4% | |
| ROA | 6.1% | 5.8% | 6.4% | 7.1% | 14.4% | 10.7% | 7.2% | 6.8% | 7.5% | 6.4% | 7.1% | 5.9% | |
| ROE | 14.2% | 13.3% | 14.0% | 15.3% | 30.2% | 23.1% | 15.8% | 14.5% | 16.2% | 13.9% | 15.8% | 13.5% | |
| ROIC | 9.2% | 8.0% | 8.9% | 11.4% | 17.5% | 13.8% | 9.1% | 9.7% | 10.2% | 9.2% | 11.1% | · |
Likidite ve Solventlik 5
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.0 | 1.1 | 1.3 | 1.2 | 1.6 | 1.7 | 1.3 | 0.9 | 1.2 | 1.6 | 1.3 | 0.9 | |
| Quick Ratio | 0.8 | 0.9 | 1.0 | 1.0 | 1.3 | 1.5 | 1.1 | 0.8 | 1.0 | 1.3 | 0.9 | 0.7 | |
| Debt / Equity | 0.8 | 0.9 | 0.7 | 0.7 | 0.6 | 0.6 | 0.8 | 0.7 | 0.8 | 0.8 | 0.8 | 0.9 | |
| LT Debt / Equity | 0.7 | 0.8 | 0.7 | 0.7 | 0.6 | 0.6 | 0.7 | 0.7 | 0.8 | 0.8 | 0.7 | 0.8 | |
| Interest Coverage | · | · | 7.7 | 9.6 | 15.7 | 11.9 | 6.8 | 6.5 | 7.6 | 8.9 | · | · |
Verimlilik 3
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.7 | 0.7 | 0.7 | 0.7 | 0.8 | 0.7 | 0.6 | 0.7 | 0.7 | 0.7 | 0.8 | 0.8 | |
| Inventory Turnover | 39.1 | 35.1 | 32.5 | 32.2 | 30.5 | 33.5 | 45.4 | 50.8 | 53.3 | 55.6 | 48.0 | 46.1 | |
| Receivables Turnover | 8.1 | 7.9 | 7.7 | 7.5 | 7.3 | 7.3 | 7.4 | 7.8 | 8.3 | 8.2 | 8.2 | 8.3 |
Büyüme Oranları 10
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 11.8% | 6.7% | -6.4% | -8.4% | 14.3% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 3.7% | -2.9% | -0.66% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 3.2% | · | · | · | · | · | · | · | · | · | · | · | |
| EPS YoY | 13.8% | 2.7% | -6.0% | -48.8% | 48.5% | · | · | · | · | · | · | · | |
| EPS CAGR 3Y | 3.2% | -20.9% | -10.6% | · | · | · | · | · | · | · | · | · | |
| EPS CAGR 5Y | -3.5% | · | · | · | · | · | · | · | · | · | · | · | |
| Net Income YoY | 13.9% | 2.0% | -9.7% | -52.6% | 39.4% | · | · | · | · | · | · | · | |
| Net Income CAGR 3Y | 1.6% | -24.1% | -15.8% | · | · | · | · | · | · | · | · | · | |
| Net Income CAGR 5Y | -7.1% | · | · | · | · | · | · | · | · | · | · | · | |
| Dividend CAGR 5Y | 3.5% | · | · | · | · | · | · | · | · | · | · | · |
Değerleme (TTM) 16
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $11.04B | $9.87B | $9.25B | $9.88B | $10.79B | $9.44B | $7.73B | $7.53B | $7.40B | $7.21B | $7.49B | $7.43B | |
| Net Income TTM | $992M | $871M | $854M | $946M | $2.00B | $1.43B | $858M | $736M | $772M | $645M | $709M | $556M | |
| Market Cap | $19.09B | $16.75B | $15.30B | $17.36B | $20.59B | $15.85B | $14.20B | $11.24B | $13.30B | $12.59B | $10.17B | $9.66B | |
| Enterprise Value | $24.34B | $22.41B | $19.33B | $21.03B | $23.73B | $18.71B | $17.78B | $15.00B | $16.94B | $15.97B | $13.69B | $13.23B | |
| P/E | 19.8 | 19.6 | 18.4 | 19.6 | 11.1 | 11.4 | 17.0 | 15.7 | 17.9 | 20.4 | 14.6 | 17.6 | |
| P/S | 1.7 | 1.7 | 1.7 | 1.8 | 1.9 | 1.7 | 1.8 | 1.5 | 1.8 | 1.7 | 1.4 | 1.3 | |
| P/B | 2.7 | 2.5 | 2.4 | 2.9 | 3.2 | 2.3 | 2.5 | 2.2 | 2.7 | 2.7 | 2.2 | 2.2 | |
| P / Cash Flow | 10.1 | 12.6 | 12.0 | 10.1 | 9.2 | 7.9 | 11.4 | 9.4 | 11.3 | 11.8 | 12.6 | 10.3 | |
| P / FCF | 14.0 | 18.4 | 17.7 | 13.2 | 11.3 | 10.0 | 16.8 | 13.8 | 14.4 | 16.2 | 18.6 | 15.3 | |
| EV / EBITDA | 11.4 | 12.2 | 11.4 | 11.3 | 8.5 | 8.0 | 11.4 | 10.6 | 11.8 | 10.5 | 8.0 | 10.2 | |
| EV / FCF | 17.9 | 24.7 | 22.4 | 16.0 | 13.0 | 11.8 | 21.1 | 18.4 | 18.4 | 20.6 | 25.0 | 21.0 | |
| EV / Revenue | 2.2 | 2.3 | 2.1 | 2.1 | 2.2 | 2.0 | 2.3 | 2.0 | 2.3 | 2.2 | 1.8 | 1.8 | |
| Dividend Yield | 1.8% | 2.0% | 2.1% | 1.8% | 1.5% | 1.9% | 2.0% | 2.4% | 1.9% | 1.8% | 2.1% | 1.9% | |
| Earnings Yield | 5.0% | 5.1% | 5.4% | 5.1% | 9.0% | 8.8% | 5.9% | 6.3% | 5.6% | 4.9% | 6.9% | 5.7% | |
| Payout Ratio | 35.6% | 38.0% | 36.8% | 32.2% | 15.5% | 20.8% | 33.3% | 36.1% | 32.0% | 34.6% | 29.9% | 33.6% | |
| Annual Payout | $353M | $331M | $314M | $305M | $309M | $297M | $286M | $266M | $247M | $223M | $212M | $187M |
Gelir Tablosu 16
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.04B | $2.90B | $2.81B | $2.82B | $2.76B | $2.65B | $2.62B | $2.49B | $2.40B | $2.37B | $2.29B | $2.29B | $2.34B | $2.33B | $2.33B | $2.49B | |
| Cost of Revenue | $2.02B | $1.95B | $1.90B | $1.87B | $1.82B | $1.79B | $1.76B | $1.68B | $1.59B | $1.59B | $1.55B | $1.54B | $1.55B | $1.56B | $1.57B | $1.62B | |
| SG&A Expense | $529M | $504M | $504M | $501M | $486M | $476M | $466M | $448M | $416M | $440M | $407M | $380M | $416M | $439M | $563M | $464M | |
| Operating Expenses | $2.58B | $2.50B | $2.42B | $2.43B | $2.32B | $2.31B | $2.26B | $2.16B | $2.04B | $2.07B | $2.02B | $1.95B | $1.99B | $2.03B | $2.20B | $2.09B | |
| Operating Income | $459M | $399M | $386M | $386M | $438M | $346M | $361M | $330M | $355M | $300M | $267M | $342M | $348M | $305M | $135M | $392M | |
| Interest Expense | · | · | · | · | · | · | · | · | $47M | $49M | · | $41M | $39M | $37M | · | $37M | |
| Interest Income | $5M | $2M | $3M | $3M | $2M | $5M | $7M | $9M | $3M | $6M | $6M | $1M | $2M | $2M | $4M | $4M | |
| Other Non-op | $16M | $-2M | $8M | $8M | $13M | $-3M | $3M | $15M | $3M | $9M | $10M | $-3M | $6M | $7M | $6M | $-8M | |
| Pretax Income | $412M | $334M | $330M | $328M | $384M | $276M | $299M | $296M | $314M | $266M | $237M | $299M | $317M | $277M | $109M | $351M | |
| Income Tax | $88M | $74M | $81M | $77M | $97M | $59M | $68M | $65M | $74M | $66M | $40M | $68M | $75M | $65M | $-4M | $81M | |
| Net Income | $320M | $252M | $245M | $245M | $282M | $220M | $222M | $226M | $229M | $194M | $192M | $225M | $235M | $202M | $101M | $256M | |
| EPS (Basic) | $2.88 | $2.27 | $2.21 | $2.18 | $2.51 | $1.97 | $1.98 | $2.01 | $2.05 | $1.74 | $1.72 | $1.99 | $2.08 | $1.80 | $0.93 | $2.20 | |
| EPS (Diluted) | $2.84 | $2.24 | $2.18 | $2.16 | $2.47 | $1.94 | $1.95 | $1.99 | $2.03 | $1.72 | $1.70 | $1.96 | $2.05 | $1.78 | $0.92 | $2.17 | |
| Shares (Basic) | 111,000,000 | 110,000,000 | -224,000,000 | 112,000,000 | 112,000,000 | 111,000,000 | -223,000,000 | 112,000,000 | 111,000,000 | 111,000,000 | -224,000,000 | 112,000,000 | 112,000,000 | 112,000,000 | -236,000,000 | 116,000,000 | |
| Shares (Diluted) | 112,000,000 | 112,000,000 | -226,000,000 | 113,000,000 | 113,000,000 | 113,000,000 | -224,000,000 | 113,000,000 | 112,000,000 | 112,000,000 | -228,000,000 | 114,000,000 | 114,000,000 | 113,000,000 | -240,000,000 | 118,000,000 | |
| EBITDA | $605M | $546M | · | $528M | $581M | $486M | · | $455M | $472M | $416M | · | $453M | $460M | $412M | · | $500M |
Bilanço 26
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $626M | $393M | $420M | $432M | $319M | $188M | $549M | $764M | $271M | $474M | · | $143M | $126M | $175M | · | $700M | |
| Receivables | $1.67B | $1.59B | $1.41B | $1.46B | $1.42B | $1.40B | $1.30B | $1.38B | $1.32B | $1.32B | · | $1.28B | $1.24B | $1.25B | · | $1.28B | |
| Inventory | $233M | $225M | $189M | $186M | $187M | $189M | $188M | $184M | $182M | $181M | · | $184M | $184M | $190M | · | $183M | |
| Prepaid Expense | $319M | $361M | $361M | $333M | $273M | $294M | $351M | $299M | $245M | $251M | · | $207M | $188M | $195M | · | $171M | |
| Current Assets | $2.84B | $2.57B | $2.38B | $2.41B | $2.20B | $2.08B | $2.39B | $2.62B | $2.02B | $2.23B | · | $1.81B | $1.73B | $1.81B | · | $2.33B | |
| PP&E (Net) | $2.22B | $2.19B | $2.20B | $2.15B | $2.12B | $2.10B | $2.11B | $2.09B | $1.83B | $1.81B | · | $1.83B | $1.81B | $1.79B | · | $1.71B | |
| PP&E (Gross) | · | · | $6.18B | · | · | · | $5.77B | · | · | · | · | · | · | · | · | · | |
| Accum. Depreciation | · | · | $3.97B | · | · | · | $3.66B | · | · | · | · | · | · | · | · | · | |
| Goodwill | $9.11B | $9.12B | $8.95B | $8.90B | $8.88B | $8.85B | $8.86B | $8.61B | $7.88B | $7.83B | $7.73B | $7.73B | $7.73B | $7.24B | $7.22B | $7.19B | |
| Intangibles | $1.67B | $1.72B | $1.64B | $1.66B | $1.71B | $1.73B | $1.76B | $1.72B | $1.20B | $1.19B | · | $1.22B | $1.25B | $1.08B | · | $1.11B | |
| Other Non-current Assets | $277M | $256M | $270M | $296M | $271M | $260M | $255M | $272M | $216M | $182M | · | $149M | $152M | $150M | · | $132M | |
| Total Assets | $16.94B | $16.67B | $16.23B | $16.20B | $15.97B | $15.80B | $16.15B | $16.09B | $13.88B | $13.95B | · | $13.48B | $13.43B | $12.79B | · | $13.22B | |
| Accounts Payable | $1.60B | $1.50B | $1.60B | $1.46B | $1.35B | $1.27B | $1.39B | $1.31B | $1.25B | $1.24B | · | $1.16B | $1.20B | $1.20B | · | $1.45B | |
| Accrued Liabilities | · | · | $338M | · | · | · | $306M | · | · | · | · | · | · | · | · | · | |
| Current Liabilities | $1.79B | $2.18B | $2.28B | $2.13B | $2.02B | $1.44B | $2.17B | $2.09B | $2.01B | $2.30B | · | $1.62B | $1.88B | $1.35B | · | $1.60B | |
| Capital Leases | $561M | $574M | $537M | $534M | $540M | $538M | $535M | $543M | $507M | $489M | · | $505M | $508M | $490M | · | $505M | |
| Other Non-current Liabilities | $1.06B | $1.02B | $957M | $982M | $890M | $917M | $938M | $891M | $811M | $817M | · | $874M | $901M | $809M | · | $787M | |
| Long-term Debt | $5.64B | · | $5.67B | · | · | · | $6.22B | $6.25B | · | · | · | · | · | · | · | · | |
| Total Debt | $5.64B | $503M | · | $504M | $504M | $1M | · | $6.25B | $606M | $906M | · | $304M | $518M | $2M | · | $2M | |
| Common Stock | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | · | $2M | $2M | $2M | · | $2M | |
| Retained Earnings | $10.37B | $10.15B | $9.99B | $9.84B | $9.68B | $9.49B | $9.36B | $9.22B | $9.08B | $8.94B | · | $8.71B | $8.57B | $8.41B | · | $8.26B | |
| Treasury Stock | $5.17B | $5.09B | $5.18B | $4.90B | $4.77B | $4.79B | $4.86B | $4.73B | $4.76B | $4.78B | · | $4.57B | $4.59B | $4.61B | · | $4.27B | |
| AOCI | $-62M | $-43M | $-27M | $-40M | $-16M | $-83M | $-88M | $-15M | $-19M | $-16M | · | $-20M | $-16M | $-18M | · | $-31M | |
| Stockholders' Equity | $7.52B | $7.37B | $7.17B | $7.26B | $7.23B | $6.93B | $6.78B | $6.81B | $6.62B | $6.43B | · | $6.42B | $6.25B | $6.05B | · | $6.24B | |
| Liabilities + Equity | $16.94B | $16.67B | $16.23B | $16.20B | $15.97B | $15.80B | $16.15B | $16.09B | $13.88B | $13.95B | · | $13.48B | $13.43B | $12.79B | · | $13.22B | |
| Shares Outstanding | 110,000,000 | 111,000,000 | 110,000,000 | 111,000,000 | 112,000,000 | 112,000,000 | 111,000,000 | 112,000,000 | 111,000,000 | 111,000,000 | 111,000,000 | 112,000,000 | 112,000,000 | 112,000,000 | 111,000,000 | 114,000,000 |
Nakit Akışı 16
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $146M | $147M | $145M | $142M | $143M | $140M | $135M | $125M | $117M | $116M | $109M | $111M | $112M | $107M | $116M | $108M | |
| Stock-based Comp | $23M | $20M | $25M | $20M | $21M | $22M | $27M | $19M | $20M | $22M | $19M | $18M | $16M | $24M | $22M | $18M | |
| Deferred Tax | $-2M | $48M | $-13M | $110M | $1M | $7M | $34M | $15M | $-18M | $-18M | $-10M | $-23M | $-12M | $-4M | $-44M | $65M | |
| Amort. of Intangibles | $38M | $37M | $37M | $39M | $39M | $39M | $37M | $32M | $29M | $29M | $27M | $27M | $28M | $26M | $39M | $27M | |
| Restructuring | · | · | · | $6M | $1M | · | · | $7M | $8M | · | · | $1M | $1M | · | · | · | |
| Other Non-cash | · | $-189M | · | · | · | $-75M | · | · | · | $-160M | · | · | · | $-235M | · | · | |
| Operating Cash Flow | $597M | $278M | $465M | $563M | $544M | $314M | $464M | $356M | $360M | $154M | $527M | $207M | $444M | $94M | $334M | $502M | |
| CapEx | $138M | $114M | $158M | $144M | $108M | $117M | $123M | $106M | $92M | $104M | $72M | $105M | $104M | $127M | $147M | $118M | |
| Investing Cash Flow | $-134M | $-152M | $-191M | $-201M | $-124M | $-115M | $-502M | $-1.63B | $-200M | $-213M | $-114M | $-107M | $-682M | $-158M | $-174M | $-118M | |
| Stock Repurchased | · | · | $300M | $150M | · | · | $151M | · | · | · | $275M | $0 | $0 | $0 | $461M | $374M | |
| Net Stock Activity | · | · | · | · | · | · | · | · | · | · | · | · | · | $0 | · | · | |
| Dividends Paid | $96M | $88M | $90M | $89M | $90M | $84M | $84M | $84M | $84M | $79M | $80M | $80M | $80M | $74M | $75M | $78M | |
| Financing Cash Flow | $-229M | $-152M | $-287M | $-247M | $-293M | $-561M | $-170M | $1.77B | $-363M | $-153M | $130M | $-83M | $189M | $-76M | $-545M | $-474M | |
| Net Change in Cash | $233M | $-27M | $-12M | $113M | $131M | $-361M | $-215M | $493M | $-203M | $-212M | $543M | $17M | $-49M | $-140M | $-385M | $-90M | |
| Free Cash Flow | · | $164M | · | · | · | $197M | · | · | · | $50M | · | · | · | $-33M | · | · | |
| Levered FCF | · | · | · | · | · | · | · | · | · | $13M | · | · | · | $-61M | · | · |
Kârlılık 7
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 15.1% | 13.8% | · | 13.7% | 15.9% | 13.1% | · | 13.3% | 14.8% | 12.7% | · | 14.9% | 14.9% | 13.1% | · | 15.8% | |
| Net Margin | 10.5% | 8.7% | · | 8.7% | 10.2% | 8.3% | · | 9.1% | 9.6% | 8.2% | · | 9.8% | 10.1% | 8.7% | · | 10.3% | |
| Pretax Margin | 13.5% | 11.5% | · | 11.7% | 13.9% | 10.4% | · | 11.9% | 13.1% | 11.2% | · | 13.0% | 13.6% | 11.9% | · | 14.1% | |
| EBITDA Margin | 19.9% | 18.9% | · | 18.8% | 21.0% | 18.3% | · | 18.3% | 19.7% | 17.6% | · | 19.7% | 19.7% | 17.7% | · | 20.1% | |
| ROA | 1.9% | 1.6% | · | 1.5% | 1.9% | 1.5% | · | 1.5% | 1.7% | 1.5% | · | 1.7% | 1.8% | 1.5% | · | 1.9% | |
| ROE | 4.3% | 3.5% | · | 3.5% | 4.1% | 3.3% | · | 3.4% | 3.6% | 3.1% | · | 3.5% | 3.7% | 3.2% | · | 4.0% | |
| ROIC | 2.7% | 4.0% | · | 3.8% | 4.2% | 3.9% | · | 2.0% | 3.8% | 3.1% | · | 3.9% | 3.9% | 3.9% | · | 4.8% |
Likidite ve Solventlik 5
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.6 | 1.2 | · | 1.1 | 1.1 | 1.4 | · | 1.3 | 1.0 | 1.0 | · | 1.1 | 0.9 | 1.3 | · | 1.5 | |
| Quick Ratio | 1.3 | 0.9 | · | 0.9 | 0.9 | 1.1 | · | 1.0 | 0.8 | 0.8 | · | 0.9 | 0.7 | 1.1 | · | 1.2 | |
| Debt / Equity | 0.8 | 0.1 | · | 0.1 | 0.1 | 0.0 | · | 0.9 | 0.1 | 0.1 | · | 0.0 | 0.1 | 0.0 | · | 0.0 | |
| LT Debt / Equity | 0.7 | · | · | · | · | · | · | 0.8 | · | · | · | · | · | · | · | · | |
| Interest Coverage | · | · | · | · | · | · | · | · | 7.6 | 6.1 | · | 8.3 | 8.9 | 8.2 | · | 10.6 |
Verimlilik 3
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.2 | 0.2 | · | 0.2 | 0.2 | 0.2 | · | 0.2 | 0.2 | 0.2 | · | 0.2 | 0.2 | 0.2 | · | 0.2 | |
| Inventory Turnover | 9.6 | 9.4 | · | 10.1 | 9.9 | 9.7 | · | 9.1 | 8.7 | 8.6 | · | 8.4 | 8.3 | 8.1 | · | 8.3 | |
| Receivables Turnover | 2.0 | 1.9 | · | 2.0 | 2.0 | 1.9 | · | 1.9 | 1.9 | 1.8 | · | 1.8 | 1.8 | 1.8 | · | 1.8 |
Değerleme (TTM) 14
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $11.52B | $11.12B | · | $10.72B | $10.30B | $9.90B | · | $9.55B | $9.40B | $9.33B | · | $9.45B | $9.61B | $9.88B | · | $10.32B | |
| Net Income TTM | $1.10B | $999M | · | $973M | $957M | $869M | · | $874M | $883M | $856M | · | $918M | $927M | $1.05B | · | $1.35B | |
| Market Cap | $23.31B | $21.75B | · | $21.15B | $20.12B | $18.95B | · | $17.39B | $15.19B | $14.78B | · | $13.65B | $15.74B | $15.85B | · | $13.99B | |
| Enterprise Value | $28.33B | $21.86B | · | $21.23B | $20.30B | $18.76B | · | $22.88B | $15.53B | $15.21B | · | $13.81B | $16.13B | $15.67B | · | $13.29B | |
| P/E | 21.8 | 22.2 | · | 22.3 | 21.3 | 22.0 | · | 20.2 | 17.6 | 17.7 | · | 15.3 | 17.7 | 16.0 | · | 11.1 | |
| P/S | 2.0 | 2.0 | · | 2.0 | 2.0 | 1.9 | · | 1.8 | 1.6 | 1.6 | · | 1.4 | 1.6 | 1.6 | · | 1.4 | |
| P/B | 3.1 | 3.0 | · | 2.9 | 2.8 | 2.7 | · | 2.6 | 2.3 | 2.3 | · | 2.1 | 2.5 | 2.6 | · | 2.2 | |
| P / Cash Flow | · | 78.3 | · | · | · | 60.4 | · | · | · | 95.9 | · | · | · | 168.6 | · | · | |
| P / FCF | · | 132.6 | · | · | · | 96.2 | · | · | · | 295.5 | · | · | · | -480.2 | · | · | |
| EV / EBITDA | 46.8 | 40.0 | · | 40.2 | 34.9 | 38.6 | · | 50.3 | 32.9 | 36.6 | · | 30.5 | 35.1 | 38.0 | · | 26.6 | |
| EV / FCF | · | 133.3 | · | · | · | 95.2 | · | · | · | 304.1 | · | · | · | -474.9 | · | · | |
| EV / Revenue | 2.5 | 2.0 | · | 2.0 | 2.0 | 1.9 | · | 2.4 | 1.7 | 1.6 | · | 1.5 | 1.7 | 1.6 | · | 1.3 | |
| Earnings Yield | 4.6% | 4.5% | · | 4.5% | 4.7% | 4.5% | · | 5.0% | 5.7% | 5.6% | · | 6.5% | 5.7% | 6.2% | · | 9.0% | |
| Payout Ratio | · | 34.9% | · | · | · | 38.2% | · | · | · | 40.7% | · | · | · | 36.6% | · | · |
Finansal Tablolar Gelir tablosu, bilanço, nakit akışı — yıllık, son 5 yıl
Gelir Tablosu
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Gelir | $11.04B | $9.87B | $9.25B | $9.88B | $10.79B |
| Faaliyet Kâr Marjı % | 14.1% | 13.6% | 13.6% | 14.4% | 22.1% |
| Net Gelir | $992M | $871M | $854M | $946M | $2.00B |
| Seyreltilmiş Hisse Başı Kâr | $8.75 | $7.69 | $7.49 | $7.97 | $15.55 |
Bilanço
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Borç / Öz Sermaye | 0.8 | 0.9 | 0.7 | 0.7 | 0.6 |
| Cari Oran | 1.0 | 1.1 | 1.3 | 1.2 | 1.6 |
| Cari Oran | 0.8 | 0.9 | 1.0 | 1.0 | 1.3 |
Nakit Akışı
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Serbest Nakit Akışı | $1.36B | $909M | $864M | $1.31B | $1.83B |
Son Haberler Bu şirketten bahseden son manşetler
Metriklerim Kişisel izleme listeniz — Tam Temeller'den seçilen satırlar
📊
Sizin için önemli olan metrikleri seçin — yukarıdaki Tam Temeller'deki herhangi bir satırın yanındaki ➕ düğmesine tıklayın.
Seçiminiz kaydedildi ve tüm hisse senetlerinde sizinle birlikte gelir.
Kurumsal Sahipler (13F) 1.176 dosya · $12.9B toplam · Tarih itibarıyla 30 Haziran 2026
Çeyreklik SEC Form 13F'lerinde bu hisse senedini tuttuklarını bildiren kurumlar. Yalnızca uzun pozisyonlar; tek bir başvuru sahibi, ayrı opsiyon bacakları için iki kez görünebilir. Büyük dengeleyici alım/satım bacakları genellikle piyasa yapımını veya korunmuş envanteri yansıtır, yönlü bir inancı değil.
Kurumsal faaliyet — Q2 2026 ve önceki çeyrek
| Yeni pozisyonlar | Çıkan pozisyonlar | Artırıldı | Azaldı | Net hisse senedi değişimi |
|---|---|---|---|---|
| 115 (-25 önceki Ç'ye göre) | 64 (-17 önceki Ç'ye göre) | 415 (+69 önceki Ç'ye göre) | 333 (-20 önceki Ç'ye göre) | +7.5M |
Q1 2026 ile karşılaştırıldı. SEC Form 13F başvuruları, çeyrek sonundan itibaren 45 gün içinde ve geç başvuranlar için kısa bir ek süre içinde tamamlanmalıdır — bu pencere içindeki çeyrekler, en son tam olarak raporlanan çifte tercih edilerek atlanır.
| Kurum | Değer | Hisse senetleri | % izlenen 13F'nin | Tür |
|---|---|---|---|---|
| VANGUARD CAPITAL MANAGEMENT LLC | $1.533.117.858 | 7.233.394 | 11,93% | Hisse senetleri |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $1.299.474.988 | 6.131.045 | 10,11% | Hisse senetleri |
| STATE STREET CORP | $1.169.252.484 | 5.516.643 | 9,10% | Hisse senetleri |
| GEODE CAPITAL MANAGEMENT, LLC | $584.135.885 | 2.767.754 | 4,54% | Hisse senetleri |
| EdgePoint Investment Group Inc. | $476.372.038 | 2.247.568 | 3,71% | Hisse senetleri |
| Grantham, Mayo, Van Otterloo & Co. LLC | $400.206.122 | 1.888.207 | 3,11% | Hisse senetleri |
| DIMENSIONAL FUND ADVISORS LP | $357.050.202 | 1.684.597 | 2,78% | Hisse senetleri |
| Davis Selected Advisers | $329.781.509 | 1.555.612 | 2,57% | Hisse senetleri |
| VICTORY CAPITAL MANAGEMENT INC | $311.037.928 | 1.467.506 | 2,42% | Hisse senetleri |
| NORGES BANK | $298.133.109 | 1.406.620 | 2,32% | Hisse senetleri |
| FMR LLC | $227.315.614 | 1.072.496 | 1,77% | Hisse senetleri |
| AMERICAN CENTURY COMPANIES INC | $173.422.135 | 818.220 | 1,35% | Hisse senetleri |
| M&G PLC | $168.677.800 | 795.650 | 1,31% | Hisse senetleri |
| VANGUARD FIDUCIARY TRUST CO | $131.756.386 | 621.639 | 1,03% | Hisse senetleri |
| ALLIANCEBERNSTEIN L.P. | $122.662.706 | 625.894 | 0,95% | Hisse senetleri |
| AMERIPRISE FINANCIAL INC | $109.652.758 | 517.352 | 0,85% | Hisse senetleri |
| Woodline Partners LP | $102.974.000 | 485.841 | 0,80% | Hisse senetleri |
| FIDUCIARY MANAGEMENT INC /WI/ | $102.489.906 | 483.557 | 0,80% | Hisse senetleri |
| Artemis Investment Management LLP | $99.175.856 | 467.921 | 0,77% | Hisse senetleri |
| CRAWFORD INVESTMENT COUNSEL INC | $97.514.204 | 460.081 | 0,76% | Hisse senetleri |
| PRINCIPAL FINANCIAL GROUP INC | $91.995.201 | 434.042 | 0,72% | Hisse senetleri |
| ENVESTNET ASSET MANAGEMENT INC | $90.834.224 | 428.564 | 0,71% | Hisse senetleri |
| SCHRODER INVESTMENT MANAGEMENT GROUP | $86.608.697 | 407.302 | 0,67% | Hisse senetleri |
| BNP PARIBAS FINANCIAL MARKETS | $83.772.178 | 395.245 | 0,65% | Hisse senetleri |
| M.D. Sass, LLC | $76.397.960 | 360.453 | 0,59% | Hisse senetleri |
| Qube Research & Technologies Ltd | $72.783.206 | 343.398 | 0,57% | Hisse senetleri |
| MACKENZIE FINANCIAL CORP | $70.641.875 | 333.295 | 0,55% | Hisse senetleri |
| Advisors Capital Management, LLC | $69.429.626 | 327.575 | 0,54% | Hisse senetleri |
| Swiss National Bank | $65.683.305 | 309.900 | 0,51% | Hisse senetleri |
| Balyasny Asset Management L.P. | $58.364.883 | 275.371 | 0,45% | Hisse senetleri |
| Mitsubishi UFJ Asset Management Co., Ltd. | $56.877.630 | 268.354 | 0,44% | Hisse senetleri |
| RHUMBLINE ADVISERS | $56.744.612 | 267.727 | 0,44% | Hisse senetleri |
| BlackRock, Inc. | $55.976.419 | 264.102 | 0,44% | Hisse senetleri |
| Sumitomo Mitsui Trust Group, Inc. | $54.809.634 | 258.597 | 0,43% | Hisse senetleri |
| VANGUARD ASSET MANAGEMENT, Ltd | $53.654.295 | 253.146 | 0,42% | Hisse senetleri |
| Quantinno Capital Management LP | $53.607.358 | 252.924 | 0,42% | Hisse senetleri |
| RAYMOND JAMES FINANCIAL INC | $53.249.860 | 251.238 | 0,41% | Hisse senetleri |
| BNP PARIBAS ASSET MANAGEMENT Holding S.A. | $52.211.551 | 246.339 | 0,41% | Hisse senetleri |
| VAN LANSCHOT KEMPEN INVESTMENT MANAGEMENT N.V. | $51.484.139 | 242.907 | 0,40% | Hisse senetleri |
| Clark Capital Management Group, Inc. | $51.259.362 | 241.846 | 0,40% | Hisse senetleri |
| Vanguard Global Advisers, LLC | $51.025.267 | 240.742 | 0,40% | Hisse senetleri |
| Legal & General Group Plc | $50.185.731 | 236.781 | 0,39% | Hisse senetleri |
| FIL Ltd | $49.419.958 | 233.168 | 0,38% | Hisse senetleri |
| NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | $49.341.000 | 232.797 | 0,38% | Hisse senetleri |
| Eurizon Capital SGR S.p.A. | $47.173.414 | 222.564 | 0,37% | Hisse senetleri |
| BARCLAYS PLC | $45.003.978 | 212.333 | 0,35% | Hisse senetleri |
| PFA Pension, Forsikringsaktieselskab | $43.579.660 | 205.613 | 0,34% | Hisse senetleri |
| Integral Health Asset Management, LLC | $42.390.000 | 200.000 | 0,33% | Hisse senetleri |
| California Public Employees Retirement System | $41.574.204 | 196.151 | 0,32% | Hisse senetleri |
| CONNING INC. | $39.578.271 | 186.734 | 0,31% | Hisse senetleri |
| SEB Asset Management AB | $38.766.863 | 182.906 | 0,30% | Hisse senetleri |
| BANK OF MONTREAL /CAN/ | $38.512.587 | 181.706 | 0,30% | Hisse senetleri |
| GOLDMAN SACHS GROUP INC | $38.322.295 | 180.808 | 0,30% | Hisse senetleri |
| Boston Partners | $35.509.632 | 167.514 | 0,28% | Hisse senetleri |
| Focus Partners Wealth | $34.616.947 | 163.327 | 0,27% | Hisse senetleri |
| STOREBRAND ASSET MANAGEMENT AS | $34.117.592 | 160.970 | 0,27% | Hisse senetleri |
| COOKSON PEIRCE & CO INC | $32.977.089 | 155.589 | 0,26% | Hisse senetleri |
| UBS Group AG | $32.934.699 | 155.389 | 0,26% | Hisse senetleri |
| BRAUN STACEY ASSOCIATES INC | $32.724.232 | 154.396 | 0,25% | Hisse senetleri |
| Willis Investment Counsel | $32.110.425 | 151.500 | 0,25% | Hisse senetleri |
| CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | $31.795.403 | 162.238 | 0,25% | Hisse senetleri |
| LPL Financial LLC | $30.325.576 | 143.079 | 0,24% | Hisse senetleri |
| APG Asset Management N.V. | $27.869.580 | 150.334 | 0,22% | Hisse senetleri |
| SILVERCREST ASSET MANAGEMENT GROUP LLC | $26.893.912 | 126.888 | 0,21% | Hisse senetleri |
| &PARTNERS | $26.382.365 | 124.363 | 0,21% | Hisse senetleri |
| JANE STREET GROUP, LLC | $25.942.680 | 122.400 | 0,20% | Alım opsiyonu |
| BANK OF AMERICA CORP /DE/ | $25.492.499 | 120.276 | 0,20% | Hisse senetleri |
| Candriam S.C.A. | $25.459.925 | 120.238 | 0,20% | Hisse senetleri |
| Squarepoint Ops LLC | $24.974.280 | 117.831 | 0,19% | Hisse senetleri |
| Gotham Asset Management, LLC | $24.911.119 | 117.533 | 0,19% | Hisse senetleri |
| Universal- Beteiligungs- und Servicegesellschaft mbH | $24.607.896 | 116.373 | 0,19% | Hisse senetleri |
| HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND | $24.569.456 | 115.921 | 0,19% | Hisse senetleri |
| Robeco Institutional Asset Management B.V. | $23.854.123 | 112.546 | 0,19% | Hisse senetleri |
| AEGON ASSET MANAGEMENT UK Plc | $22.866.862 | 107.888 | 0,18% | Hisse senetleri |
| TOCQUEVILLE ASSET MANAGEMENT L.P. | $22.670.926 | 106.964 | 0,18% | Hisse senetleri |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | $22.530.921 | 106.303 | 0,18% | Hisse senetleri |
| MERCER GLOBAL ADVISORS INC /ADV | $22.106.507 | 104.301 | 0,17% | Hisse senetleri |
| Moran Wealth Management, LLC | $22.053.609 | 104.051 | 0,17% | Hisse senetleri |
| ABN AMRO Bank N.V. | $21.523.733 | 101.667 | 0,17% | Hisse senetleri |
| VIRGINIA RETIREMENT SYSTEMS ET Al | $21.496.202 | 123.876 | 0,17% | Hisse senetleri |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $21.322.170 | 100.600 | 0,17% | Alım opsiyonu |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | $21.146.252 | 99.770 | 0,16% | Hisse senetleri |
| AVIVA PLC | $20.378.569 | 96.148 | 0,16% | Hisse senetleri |
| SCHWARTZ INVESTMENT COUNSEL INC | $20.326.005 | 95.900 | 0,16% | Hisse senetleri |
| Boston Common Asset Management, LLC | $20.282.767 | 95.696 | 0,16% | Hisse senetleri |
| CAPTRUST FINANCIAL ADVISORS | $20.146.790 | 95.054 | 0,16% | Hisse senetleri |
| Midwest Trust Co | $20.113.207 | 94.896 | 0,16% | Hisse senetleri |
| LAZARD ASSET MANAGEMENT LLC | $20.035.210 | 94.528 | 0,16% | Hisse senetleri |
| FJARDE AP-FONDEN /FOURTH SWEDISH NATIONAL PENSION FUND | $19.842.759 | 93.620 | 0,15% | Hisse senetleri |
| BLAIR WILLIAM & CO/IL | $19.773.115 | 93.291 | 0,15% | Hisse senetleri |
| STATE BOARD OF ADMINISTRATION OF FLORIDA RETIREMENT SYSTEM | $19.613.005 | 92.536 | 0,15% | Hisse senetleri |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $19.160.280 | 90.400 | 0,15% | Satım opsiyonu |
| CITADEL ADVISORS LLC | $18.821.160 | 88.800 | 0,15% | Alım opsiyonu |
| WELLINGTON MANAGEMENT GROUP LLP | $17.507.282 | 82.601 | 0,14% | Hisse senetleri |
| Foundry Partners, LLC | $17.338.432 | 102.473 | 0,13% | Hisse senetleri |
| MARSHALL WACE, LLP | $17.187.874 | 81.094 | 0,13% | Hisse senetleri |
| Coho Partners, Ltd. | $16.981.317 | 89.103 | 0,13% | Hisse senetleri |
| Copeland Capital Management, LLC | $16.902.800 | 79.749 | 0,13% | Hisse senetleri |
| CIBC Asset Management Inc | $16.674.318 | 78.671 | 0,13% | Hisse senetleri |
| Mitsubishi UFJ Trust & Banking Corp | $16.558.594 | 78.125 | 0,13% | Hisse senetleri |
Şirket yöneticileri 53 içeriden öğrenenler · 26 yöneticiler · 26 yönetim kurulu üyeleri
| İçeriden Öğrenen | Rol | Son işlem | Sahip olunan hisse senetleri | Alımlar 12ay | Satışlar 12ay | Net 12ay |
|---|---|---|---|---|---|---|
| E. J. Davis | CEO and President | 01 Haziran 2026 S | 132.423 | 0 | 5 | $-14.656.302 |
| Surya N Mohapatra | Chairman, President & CEO | 30 Nisan 2012 F | 243.713 | 0 | 0 | $0 |
| Sam Samad | Executive Vice President & CFO | 22 Temmuz 2026 A | 33.478 | 0 | 0 | $0 |
| Mark Guinan | Executive Vice President & CFO | 07 Mart 2022 F | 98.981 | 0 | 0 | $0 |
| Robert Hagemann | SVP & Chief Financial Officer | 05 Mart 2013 F | 126.722 | 0 | 0 | $0 |
| Mark E Delaney | SVP & Chief Commercial Officer | 28 Temmuz 2026 S | 10.335 | 0 | 1 | $-376.288 |
| Karthik Kuppusamy | SVP, Clinical Solutions | 22 Temmuz 2026 L | 13.557 | 0 | 2 | $-2.167.772 |
| Patrick Plewman | SVP for Diagnostic Services | 22 Temmuz 2026 L | 15.293 | 0 | 4 | $-2.194.322 |
| Catherine T. Doherty | EVP, Regional Businesses | 05 Mart 2026 S | 67.122 | 0 | 7 | $-6.671.228 |
| Michael E Prevoznik | SVP & General Counsel | 05 Mart 2026 S | 37.557 | 0 | 7 | $-6.505.199 |
| Michael J Deppe | SVP, Corp. Controller & CAO | 04 Mart 2026 F | 35.196 | 0 | 0 | $0 |
| Mark A Gardner | SVP of Molecular Gen & Oncol | 24 Eylül 2024 F | 4.673 | 0 | 0 | $0 |
| Manner Carrie Eglinton | SVP, Advanced Diagnostics | 07 Mart 2022 F | 48.391 | 0 | 0 | $0 |
| Manuel O. Mendez | SVP & Chief Commercial Officer | 17 Şubat 2021 A | 29.045 | 0 | 0 | $0 |
| Robert A Klug | VP, Corporate Controller | 01 Mart 2019 F | 6.261 | 0 | 0 | $0 |
| Jon R Cohen | SVP & Group Exec. Diag. Sol. | 08 Mart 2018 M | 31.757 | 0 | 0 | $0 |
| Everett Cunningham | SVP, Commercial | 01 Mart 2018 G | 37.760 | 0 | 0 | $0 |
| Thomas F Bongiorno | VP and Corporate Controller | 02 Mart 2015 F | 11.837 | 0 | 0 | $0 |
| John B. Haydon | SVP, Operations | 13 Şubat 2014 A | 19.890 | 0 | 0 | $0 |
| Kathy Ordonez | SVP, Diagnostic Solutions | 31 Mart 2013 F | 9.569 | 0 | 0 | $0 |
| Joan Elizabeth Miller | SVP-Oncology & Neurology Srvcs | 29 Şubat 2012 F | 89.232 | 0 | 0 | $0 |
| Wayne R. Simmons | Vice President, Operations | 16 Haziran 2011 M | 47.150 | 0 | 0 | $0 |
| Robert E Peters | VP, Sales & Marketing | 12 Şubat 2007 A | 12.974 | 0 | 0 | $0 |
| David M Zewe | SVP, Diagnostic Testing Ops | 12 Şubat 2007 A | 31.079 | 0 | 0 | $0 |
| GRANT THOMAS W II | Sr VP, Ins. & Employer Serv. | 12 Şubat 2007 A | — | 0 | 0 | $0 |
| Gerald C Marrone | SVP, Administration | 28 Şubat 2004 F | 49.609 | 0 | 0 | $0 |
| Wright Lassiter III | Yönetim kurulu üyesi | 22 Temmuz 2026 L | 10.323 | 0 | 0 | $0 |
| Vicky B Gregg | Yönetim kurulu üyesi | 22 Temmuz 2026 A | 18.386 | 0 | 1 | $-239.700 |
| Robert B Carter | Yönetim kurulu üyesi | 22 Temmuz 2026 L | 3.864 | 0 | 0 | $0 |
| Timothy L Main | Yönetim kurulu üyesi | 22 Temmuz 2026 L | 22.460 | 0 | 0 | $0 |
| Timothy C Wentworth | Yönetim kurulu üyesi | 01 Temmuz 2026 A | 1.358 | 0 | 0 | $0 |
| Timothy M Ring | Yönetim kurulu üyesi | 20 Mayıs 2026 A | 31.140 | 0 | 0 | $0 |
| Gary M Pfeiffer | Yönetim kurulu üyesi | 20 Mayıs 2026 A | 31.005 | 0 | 1 | $-270.317 |
| Luis Diaz | Yönetim kurulu üyesi | 15 Mayıs 2025 A | 4.054 | 0 | 0 | $0 |
| Tracey Doi | Yönetim kurulu üyesi | 15 Mayıs 2025 A | 6.490 | 0 | 0 | $0 |
| Gail R Wilensky | Yönetim kurulu üyesi | 17 Mayıs 2023 A | 20.506 | 0 | 0 | $0 |
| Stephen H Rusckowski | Yönetim kurulu üyesi | 06 Mart 2023 F | 389.597 | 0 | 0 | $0 |
| Helen Torley | Yönetim kurulu üyesi | 25 Mayıs 2021 A | 6.260 | 0 | 0 | $0 |
| Daniel Stanzione | Yönetim kurulu üyesi | 23 Kasım 2020 S | 28.349 | 0 | 0 | $0 |
| Jenne K Britell | Yönetim kurulu üyesi | 04 Haziran 2018 G | 14.479 | 0 | 0 | $0 |
| Jeffrey M Leiden | Yönetim kurulu üyesi | 29 Mayıs 2018 S | 6.000 | 0 | 0 | $0 |
| John B Ziegler | Yönetim kurulu üyesi | 22 Şubat 2017 S | 16.557 | 0 | 0 | $0 |
| John C Baldwin MD | Yönetim kurulu üyesi | 12 Ağustos 2015 S | 12.949 | 0 | 0 | $0 |
| William F Buehler | Yönetim kurulu üyesi | 12 Şubat 2014 M | 26.225 | 0 | 0 | $0 |
| GSK plc | Yönetim kurulu üyesi | 31 Ocak 2011 S | 0 | 0 | 0 | $0 |
| Rosanne Haggerty | Yönetim kurulu üyesi | 06 Mayıs 2010 A | 9.334 | 0 | 0 | $0 |
| William R Grant | Yönetim kurulu üyesi | 01 Nisan 2007 A | 3.334 | 0 | 0 | $0 |
| James F Flaherty III | Yönetim kurulu üyesi | 04 Mayıs 2006 A | 1.667 | 0 | 0 | $0 |
| Kenneth D Brody | Yönetim kurulu üyesi | 28 Nisan 2004 S | 0 | 0 | 0 | $0 |
| Mary A Cirillo | Yönetim kurulu üyesi | 01 Nisan 2004 A | 2.627 | 0 | 0 | $0 |
SEC Form 3/4/5 başvurularından yöneticiler; net = yalnızca açık piyasa Alış/Satış
Aktivistler ve %5+ sahipler 13 pozisyon
SEC Çizelge 13D dosyalayan yatırımcılar — ihraççı üzerinde nüfuz etme niyetiyle %5'in üzerinde faydalı sahiplik (aktivist hisseler, yönetim kurulu kampanyaları, M&A). Her satır, o başvuru sahibinin pozisyonunun bilinen en son durumunu gösterir.
| Başvuru sahibi | Dosyalandı | Hisse | Durum | Amaç | Başvuru |
|---|---|---|---|---|---|
| Quest Diagnostics Incorporated | 18 Mayıs 2011 | — | İlk başvuru | M&A / satış | SEC |
| Açıklanmayan raporlama kişisi | 01 Şubat 2011 | — | İlk başvuru | Pasif yatırım | SEC |
| Açıklanmayan raporlama kişisi | 20 Mart 2009 | — | İlk başvuru | — | SEC |
| GlaxoSmithKline plc ×2 başvurular | 18 Eylül 2008 | — | İlk başvuru | — | SEC |
| Açıklanmayan raporlama kişisi | 16 Şubat 2007 | — | İlk başvuru | — | SEC |
| Quest Diagnostics Incorporated - (FEIN No. ×2 başvurular | 19 Ocak 2006 | — | İlk başvuru | — | SEC |
| Açıklanmayan raporlama kişisi | 15 Aralık 2004 | — | İlk başvuru | — | SEC |
| Açıklanmayan raporlama kişisi | 29 Haziran 2004 | — | İlk başvuru | — | SEC |
| Açıklanmayan raporlama kişisi | 24 Haziran 2002 | — | İlk başvuru | M&A / satış | SEC |
| Açıklanmayan raporlama kişisi | 22 Mayıs 2002 | — | İlk başvuru | — | SEC |
| Açıklanmayan raporlama kişisi | 12 Nisan 2002 | — | İlk başvuru | M&A / satış | SEC |
| IRS Identification Nos. of Above Persons (entities only) Quest Diagnostics Ventures LLC - (FEIN No., Quest Diagnostics Incorporated - (FEIN No. ×3 başvurular | 01 Kasım 2001 | — | İlk başvuru | M&A / satış | SEC |
| Açıklanmayan raporlama kişisi | 14 Mayıs 2001 | — | İlk başvuru | — | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
ETF sahipliği 185 ETF'ler tarafından tutuluyor
Ağırlık yalnızca doğrudan öz sermaye varlıklarını (N-PORT) yansıtır; kaldıraçlı veya türev tabanlı fonlar gösterilmeyen ek swap pozisyonlarına sahip olabilir.
| Fon | Ağırlık | Birimler | Tarih itibarıyla | Kaynak |
|---|---|---|---|---|
| IHF · iShares Trust | 3,93% | 198.579 SH | 20 Ağustos 2026 | Günlük |
| RSPH · Invesco Exchange-Traded Fund Trust | 1,68% | 57.951 SH | 20 Ağustos 2026 | Günlük |
| FXH · First Trust Exchange-Traded AlphaDE… | 1,29% | 57.932 NS | 30 Nisan 2026 | N-PORT |
| CZA · Invesco Exchange-Traded Fund Trust | 1,24% | 9.488 SH | 20 Ağustos 2026 | Günlük |
| TMFX · RBB Fund, Inc. | 1,05% | 1.724 NS | 31 Mayıs 2026 | N-PORT |
| ANEW · ProShares Trust | 0,92% | 364 NS | 31 Mayıs 2026 | N-PORT |
| QLTY · GMO ETF Trust | 0,85% | 196.208 NS | 31 Mayıs 2026 | N-PORT |
| ALTL · Pacer Funds Trust | 0,82% | 4.047 NS | 30 Nisan 2026 | N-PORT |
| LSEQ · Harbor ETF Trust | 0,80% | 635 NS | 30 Nisan 2026 | N-PORT |
| SPVM · Invesco Exchange-Traded Fund Trust | 0,77% | 4.426 SH | 20 Ağustos 2026 | Günlük |
| QLV · FlexShares Trust | 0,74% | 6.461 NS | 30 Nisan 2026 | N-PORT |
| GDOC · Goldman Sachs ETF Trust | 0,72% | 741 NS | 31 Mayıs 2026 | N-PORT |
| ESMV · iShares Trust | 0,72% | 236 SH | 20 Ağustos 2026 | Günlük |
| HUSV · First Trust Exchange-Traded Fund III | 0,52% | 1.956 NS | 30 Nisan 2026 | N-PORT |
| PRAY · FIS Trust | 0,47% | 1.958 NS | 31 Mayıs 2026 | N-PORT |
| ITAN · EA Series Trust | 0,46% | 2.110 NS | 29 Mayıs 2026 | N-PORT |
| BTAL · AGF Investments Trust | 0,46% | 6.072 NS | 30 Haziran 2026 | N-PORT |
| QQWZ · Pacer Funds Trust | 0,44% | 1.055 NS | 30 Nisan 2026 | N-PORT |
| COWZ · Pacer Funds Trust | 0,44% | 409.814 NS | 30 Nisan 2026 | N-PORT |
| SIXL · EXCHANGE TRADED CONCEPTS TRUST | 0,41% | 3.999 NS | 31 Mayıs 2026 | N-PORT |
| IYH · iShares Trust | 0,41% | 64.443 SH | 20 Ağustos 2026 | Günlük |
| VOE · VANGUARD INDEX FUNDS | 0,40% | 711.079 SH | 19 Ağustos 2026 | Günlük |
| JPUS · J.P. Morgan Exchange-Traded Fund Tr… | 0,38% | 8.682 NS | 30 Nisan 2026 | N-PORT |
| JPME · J.P. Morgan Exchange-Traded Fund Tr… | 0,37% | 8.368 NS | 30 Nisan 2026 | N-PORT |
| IMCV · iShares Trust | 0,36% | 18.030 SH | 20 Ağustos 2026 | Günlük |
| SUSA · iShares Trust | 0,35% | 59.963 SH | 20 Ağustos 2026 | Günlük |
| FHLC · FIDELITY COVINGTON TRUST | 0,35% | 51.278 NS | 30 Nisan 2026 | N-PORT |
| FTA · First Trust Exchange-Traded AlphaDE… | 0,34% | 23.030 NS | 30 Nisan 2026 | N-PORT |
| VHT · VANGUARD WORLD FUND | 0,34% | 330.273 SH | 19 Ağustos 2026 | Günlük |
| IXJ · iShares Trust | 0,32% | 58.047 SH | 20 Ağustos 2026 | Günlük |
| RXL · ProShares Trust | 0,31% | 1.147 NS | 31 Mayıs 2026 | N-PORT |
| CURE · Direxion Shares ETF Trust | 0,31% | 2.194 NS | 30 Nisan 2026 | N-PORT |
| GNOM · Global X Funds | 0,28% | 789 NS | 31 Mayıs 2026 | N-PORT |
| DFLV · Dimensional ETF Trust | 0,26% | 79.983 NS | 30 Nisan 2026 | N-PORT |
| BSCT · Invesco Exchange-Traded Self-Indexe… | 0,26% | 7.703.000 | 19 Ağustos 2026 | Günlük |
| IWS · iShares Trust | 0,25% | 166.379 SH | 20 Ağustos 2026 | Günlük |
| FEX · First Trust Exchange-Traded AlphaDE… | 0,24% | 18.806 NS | 30 Nisan 2026 | N-PORT |
| JVAL · J.P. Morgan Exchange-Traded Fund Tr… | 0,24% | 8.995 NS | 30 Nisan 2026 | N-PORT |
| EQIN · Columbia ETF Trust I | 0,23% | 3.340 NS | 30 Nisan 2026 | N-PORT |
| JMOM · J.P. Morgan Exchange-Traded Fund Tr… | 0,23% | 26.229 NS | 30 Nisan 2026 | N-PORT |
| SIZE · iShares Trust | 0,23% | 4.242 SH | 20 Ağustos 2026 | Günlük |
| DFVE · DoubleLine ETF Trust | 0,23% | 351 NS | 30 Haziran 2026 | N-PORT |
| VO · VANGUARD INDEX FUNDS | 0,23% | 2.398.948 SH | 19 Ağustos 2026 | Günlük |
| BFOR · ALPS ETF Trust | 0,22% | 2.467 NS | 31 Mayıs 2026 | N-PORT |
| EUSA · iShares, Inc. | 0,22% | 18.045 SH | 20 Ağustos 2026 | Günlük |
| RSP · Invesco Exchange-Traded Fund Trust | 0,22% | 914.353 SH | 20 Ağustos 2026 | Günlük |
| VFMV · VANGUARD WELLINGTON FUND | 0,22% | 4.307 SH | 19 Ağustos 2026 | Günlük |
| ACWV · iShares, Inc. | 0,21% | 29.381 SH | 20 Ağustos 2026 | Günlük |
| GSEW · Goldman Sachs ETF Trust | 0,20% | 18.310 NS | 31 Mayıs 2026 | N-PORT |
| DEUS · DBX ETF Trust | 0,20% | 2.734 NS | 29 Mayıs 2026 | N-PORT |